ClinicalTrials.gg

Program

Charcoal

Also written as “AST-120”, “charcoal” and “Z7200 with oral activated charcoal”.

Its studies are mostly in Multiple Sclerosis · Renal Insufficiency, Chronic · Asthma · Pouchitis · Hepatic Encephalopathy, led by 2 companies.

Furthest: phase 3, since May 1, 20069 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Keenova Therapeutics70 open or runningphase 3since May 1, 2006May 1, 2006none ahead
Zambon SpA20 open or runningphase 1since Sep 2, 2014Sep 2, 2014none ahead

Also a collaborator on its studies: kureha-corporation, Kyntra Bio and toray-industries-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 1, 2006First study: phase 3 study in Inflammatory Bowel DiseasesNew to Keenova TherapeuticsKeenova Therapeutics · NCT00321412 · 191 enrolled · United States, Austria, Belgium and more
  2. Nov 9, 2007Phase 2 study in Hepatic EncephalopathyKeenova Therapeutics · NCT00558038 · 40 enrolled · United States
  3. Dec 20, 20074 phase 2 studiesKeenova Therapeutics · NCT00583531, NCT00583128, NCT00583076 and 1 more
  4. Mar 20, 2009Phase 2 study in Hepatic EncephalopathyKeenova Therapeutics · NCT00867698 · 148 enrolled · United States
  5. Sep 2, 2014Zambon SpA's first study: phase 1 study in AsthmaNew to Zambon SpAZambon SpA · NCT02237508 · 90 enrolled · United Kingdom
  6. Dec 14, 2015Phase 1 study in AsthmaZambon SpA · NCT02631941 · 91 enrolled · United Kingdom

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT02631941Asthma · United Kingdom1CompletedZambon SpAJul 201691
NCT02237508Asthma · United Kingdom1CompletedZambon SpAFeb 201590
NCT00867698Hepatic Encephalopathy · United States2CompletedKeenova TherapeuticsApr 2010148
NCT00587275Gastroesophageal Reflux · United States2TerminatedKeenova TherapeuticsJun 20084
NCT00583531Pouchitis · United States2TerminatedKeenova TherapeuticsDec 20082
NCT00583128Irritable Bowel Syndrome · United States, Belgium2CompletedKeenova TherapeuticsMay 2010117
NCT00583076Pouchitis · United States2CompletedKeenova TherapeuticsMar 200819
NCT00558038Hepatic Encephalopathy · United States2CompletedKeenova TherapeuticsMar 200940
NCT00321412Inflammatory Bowel Diseases · United States, Austria, Belgium and more3CompletedKeenova TherapeuticsMar 2008191

How it is read

Names in the registry

  • “AST-120”, 10 entries
  • “charcoal”, 2 entries
  • “Z7200 with oral activated charcoal”, 2 entries
  • “Symbicort Turbohaler with oral activated charcoal”, 1 entry
  • “Activated Charcoal”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.